Short-course treatment for drug-resistant tuberculosis
Part of Infections clinical trials.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and weigh at least 30 kg.
- Your TB must be confirmed resistant to rifampicin by a lab test in the last 3 months.
- You must agree to HIV testing and, if HIV positive, to take antiretroviral therapy.
- If you are a woman able to have children, you must have a negative pregnancy test and use effective birth control during the study and for 3 months after.
- You must not have serious heart, liver, kidney, or nerve problems that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests a very short treatment for active lung TB in people aged 65 and older. The goal is to see if a short course of medicines can effectively cure TB without side effects.
This trial tests a 6-month all-oral combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin) for people with drug-resistant tuberculosis. It aims to see if this shorter, simpler regimen works well and is safe.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.